Markets:

Overview

News

Currencies

International

Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

62.90 -0.41 (-0.65%)

Delayed Quote Updated: 2:09 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial ↗

June 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026

June 22, 2022

Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It...

Via FinancialNewsMedia

Where Cytokinetics Stands With Analysts ↗

May 24, 2022

Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings:

Via Benzinga

Cytokinetics Posts Cohort 3 Data From Aficamten Trial In Heart Disease Patients ↗

February 01, 2022

Cytokinetics Incorporated (NASDAQ: CYTK) has announced

Via Benzinga

Expert Ratings For Cytokinetics ↗

October 07, 2021

Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings with...

Via Benzinga

What 5 Analyst Ratings Have To Say About Cytokinetics ↗

June 10, 2022

Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings:

Via Benzinga

The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More ↗

May 22, 2022

Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support.

Via Benzinga

Top Biotech Stocks: Trading Opportunities For Next Week - Sunday, May 22 ↗

May 22, 2022

A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some biotech stock opportunities by analyzing...

Via Talk Markets

Why Orphan Drug Designation Offers Several Benefits

May 18, 2022

Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation. Here we...

Via FinancialNewsMedia

The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation ↗

May 17, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

May 16, 2022

Needham cut the price target on Carvana Co. (NYSE: CVNA) from $121 to $80. Carvana shares rose 11.3% to $42.71 in pre-market trading.

Via Benzinga

Cytokinetics: Q1 Earnings Insights ↗

May 04, 2022

Cytokinetics (NASDAQ:CYTK) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cytokinetics missed estimated...

Via Benzinga

Cytokinetics's Omecamtiv Mecarbil Shows No Effect On Exercise Capacity In Heart Failure Patients ↗

April 04, 2022

Via Benzinga

70 Biggest Movers From Friday ↗

May 02, 2022

Gainers GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners. Vaxxinity, Inc. (NASDAQ: VAXX)...

Via Benzinga

Cytokinetics: Q4 Earnings Insights ↗

February 24, 2022

Cytokinetics (NASDAQ:CYTK) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

48 Stocks Moving In Friday's Mid-Day Session ↗

April 29, 2022

Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS. GTY Technology Holdings Inc. (NASDAQ:...

Via Benzinga

33 Stocks Moving In Friday's Mid-Day Session ↗

January 07, 2022

Gainers Marin Software Incorporated (NASDAQ: MRIN) shares climbed 35.9% to $4.6899 after the company announced an integration with Amazon Ads' demand-side platform. Absci...

Via Benzinga

The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More ↗

March 27, 2022

Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.

Via Benzinga

Week In Review: BeiGene Out-Licenses TIGIT Inhibitor To Novartis In $2.8 Billion Pact ↗

December 26, 2021

Beijing BeiGene out-licensed ex-China rights for its TIGIT inhibitor to Novartis in a multi-faceted $2.8 billion deal. As part of the agreement, BeiGene will have rights to market five Novartis...

Via Talk Markets

56 Biggest Movers From Friday ↗

January 10, 2022

Gainers Hour Loop, Inc. (NASDAQ: HOUR) shares jumped 99.8% to $7.99 after the company priced its IPO at $4 per share. China HGS Real Estate Inc. (NASDAQ: HGSH) shares...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2021 ↗

December 22, 2021

Upgrades According to Loop Capital, the prior rating for Williams-Sonoma Inc (NYSE:

Via Benzinga

What 5 Analyst Ratings Have To Say About Cytokinetics ↗

December 10, 2021

Analysts have provided the following ratings for Cytokinetics (NASDAQ:CYTK)...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021 ↗

December 10, 2021

Upgrades According to JP Morgan, the prior rating for Arconic Corp (NYSE:

Via Benzinga

The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré ↗

December 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome...

Via Benzinga

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

Cytokinetics, Incorporated (CYTK) Q3 2021 Earnings Call Transcript ↗

November 04, 2021

CYTK earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Where Cytokinetics Stands With Analysts ↗

October 08, 2021

Over the past 3 months, 6 analysts have published their opinion on Cytokinetics (NASDAQ:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021 ↗

October 07, 2021

Upgrades For State Street Corporation (NYSE:

Via Benzinga

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs ↗

October 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...

Via Benzinga

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗

October 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.